Browse News
Filter News
Found 409 articles
-
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
9/6/2023
Guardant Health, Inc., a leading precision oncology company, announced that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease test.
-
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
9/5/2023
Guardant Health Receives Regulatory Approval in Japan for Guardant360 ® CDx as Companion Diagnostic to ENHERTU ® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations.
-
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
9/1/2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study.
-
Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
8/31/2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, New York.
-
Liquid Biopsy Market Demand is Set to Grow at 14.5% till 2032
8/25/2023
The global liquid biopsy market is evaluated at USD 4,722.73 million for the year 2022 and is projected to grow at a CAGR of 14.5% to reach a market size of USD 18,280.13 million by the year 2032, study published by Towards Healthcare.
-
Guardant Health to Host Investor Day on September 7, 2023
8/17/2023
Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, announced the company will be hosting an Investor Day on September 7, 2023, in New York City, NY starting at 8:00 a.m. Eastern time / 5:00 a.m. Pacific Time.
-
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
8/3/2023
Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, reported financial results for the quarter ended June 30, 2023.
-
Following a year-long legal battle, Illumina is dropping the intellectual property allegations against Guardant. The companies have also entered into a new long-term purchase and supply commitment.
-
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
8/1/2023
Guardant Health, Inc. announced an agreement with Illumina Inc., a global leader in DNA sequencing and array-based technologies, that resolves their pending litigation and promotes a shared resolution to advance the companies’ long-term, commercial partnership.
-
Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana
7/20/2023
Guardant Health, Inc., a leading precision oncology company, announced that Blue Cross and Blue Shield of Louisiana now offers coverage for the Guardant Reveal™ molecular residual disease test.
-
Guardant Health to Report Second Quarter 2023 Financial Results on August 3, 2023
7/12/2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will report financial results for the second quarter of 2023 after market close on Thursday, August 3, 2023.
-
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
7/5/2023
Guardant Health announces reimbursement approval of Guardant360 ® CDx liquid biopsy test in Japan.
-
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
5/31/2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data from 17 studies that highlight the contribution of Guardant blood tests and real-world data to advances in precision oncology and cancer screening at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago.
-
Colorectal Cancer Market to reach USD 22.95Bn by 2027 to grow with a CAGR of 4.0% from 2019-2027
5/30/2023
According to The Insight Partners market research titled 'Colorectal Cancer Market to 2027 – Global Analysis and Forecasts by Modality, and End User'.
-
Guardant Health to Participate in Upcoming June 2023 Investor Conferences
5/26/2023
Guardant Health, Inc., a leading precision oncology company, announced the company will be participating in the following investor conferences.
-
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock - May 23, 2023
5/23/2023
Guardant Health, Inc., a leading precision oncology company, announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions.
-
Guardant Health Announces Proposed Public Offering of Common Stock - May 22, 2023
5/22/2023
Guardant Health, Inc., a leading precision oncology company, announced that it has commenced an underwritten public offering of $250.0 million of its common stock.
-
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
5/17/2023
Guardant Health, Inc., a leading precision oncology company, announced that it has received new commercial health plan coverage for the Guardant360 liquid biopsy test from Anthem Blue Cross and Blue Shield, Aetna and Humana.
-
Exact Sciences Extends Leadership in Colorectal Cancer Screening with New Data Presented at Digestive Disease Week® Annual Meeting
5/9/2023
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, presented new data supporting the company's research and innovation in colorectal cancer during Digestive Disease Week® 2023, May 6-9 in Chicago, Illinois.
-
Guardant Health Reports First Quarter 2023 Financial Results
5/9/2023
Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, reported financial results for the quarter ended March 31, 2023.